Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Davies, Stella M  [Clear All Filters]
Journal Article
Khandelwal P, Bleesing JJ, Davies SM, Marsh RA. A Single Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced Intensity Conditioning to Myeloablative Busulfan, Cyclophosphamide, and Anti-Thymocyte Globulin for Chronic Granulomatous Disease. Biol Blood Marrow Transplant. 2016.
Klages KL, Schwartz LE, Crabtree EJSantee, Brokamp C, Rasnick E, Dandoy CE, Davies SM, Pai ALH. Social determinants of health predict health outcomes following pediatric allogeneic hematopoietic stem cell transplant. Pediatr Blood Cancer. 2024:e30892.
Jodele S, Dandoy CE, Danziger-Isakov L, Myers KC, El-Bietar J, Nelson A, Wallace G, Teusink-Cross A, Davies SM. Terminal complement blockade after HSCT is safe without meningococcal vaccination. Biol Blood Marrow Transplant. 2016.
Galletta TJ, Lane A, Lutzko C, Leemhuis T, Cancelas JA, Khoury R, Wang YZM, Hanley PJ, Keller MD, Bollard CM, et al. Third party and patient-specific donor-derived virus-specific T cells demonstrate similar efficacy and safety for management of viral infections after hematopoietic stem cell transplant in children and young adults. Transplant Cell Ther. 2023.
Khoury R, Grimley MS, Nelson AS, Leemhuis T, Cancelas JA, Cook E, Wang YZ, Heyenbruch D, Bollard CM, Keller MD, et al. Third-party virus specific T cells for the treatment of double stranded DNA viral reactivation and PTLD after solid organ transplant. Am J Transplant. 2024.
Wallace G, Jodele S, Howell J, Myers KC, Teusink A, Zhao X, Setchell K, Holtzapfel C, Lane A, Taggart C, et al. Vitamin D Deficiency and Survival in Children after Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2015.

Pages